Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Chronic myelogenous leukemia Stories

2012-12-10 16:24:12

EAST HANOVER, N.J., Dec. 10, 2012 /PRNewswire/ -- The latest results from two Phase III clinical trials further establish the benefits of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to Tasigna after long-term treatment with Gleevec. Findings from both studies were presented in oral sessions...

2012-12-10 16:55:13

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair. Now,...

2012-12-10 16:41:33

Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have provided unprecedented opportunities for the...

2012-12-09 08:20:16

ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have...

2012-12-06 16:23:34

BLUE BELL, Pa., Dec. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are...

2012-11-29 14:56:43

HOUSTON — A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine. All 12 patients in the trial with chronic phase CML and the T315I mutation had a complete hematologic response (absence of CML cells in the blood) after treatment with ponatinib. Eleven had a major reduction in CML cells in the bone marrow and nine achieved a...

2012-11-28 00:22:09

EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ -- Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases. The American Society of Hematology (ASH) annual meeting in Atlanta, held December 8-11, will feature significant data across...

2012-11-08 08:35:29

VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals (BC) Ltd. (DelMar) today announced that Mr. Jeffrey Bacha, the Company's President & CEO, delivered the keynote address entitled VAL-083 a Novel Chemotherapeutic Agent Developed in China for CML and Lung Cancer Shows Potential to Surpass Standard of Care in Glioblastoma Multiforme at the 2012 International Drug Discovery Science and Technology Conference in Nanjing, China. In his address, Mr. Bacha...

2012-09-28 02:24:36

NEW YORK, Sept. 28, 2012 /PRNewswire/ -- There are two common dilemmas in the treatment of cancer today: the first is that many therapies, including chemotherapies and radiation can debilitate healthy cells, to the point of killing the person before defeating the cancer. The second problem is that many cancer cells, responding to a prevention drug, can quickly mutate to become immune and more resilient. Recent advances in circulating tumor cell technology (CTC) however, headed by...

2012-09-12 02:29:20

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API) announced today that Geraldine Henwood, an experienced biopharmaceutical executive, joined the Company's management team in the consultative capacity of Chief Development Officer, Iomab-B. Ms. Henwood will spearhead efforts on further development of its clinical stage Iomab-B drug candidate. Iomab-B is a monoclonal antibody construct in-licensed by API from Fred Hutchinson Cancer Research Center in Seattle. It is...